Covista Inc.
CVSA
$117.51
-2.68%
Covista Inc. is an American healthcare educator operating five accredited institutions and serving more than 97,000 students, with a business model built on personalized, tech-enabled education that expands access to healthcare careers and addresses the U.S. healthcare workforce shortage at scale. The company occupies a distinct position as a scaled, multi-institution platform in the post-secondary healthcare education niche, competing against both traditional non-profit universities and other for-profit education providers. The current investor narrative centers on the durability of enrollment-driven revenue growth and margin expansion, with the stock having recently pulled back sharply from its 52-week highs despite a still-positive six-month trend. Debate among the small analyst cohort focuses on whether the company's operating leverage and aggressive share repurchases can sustain earnings growth as revenue growth moderates to the mid-single-digit range.…
CVSA
Covista Inc.
$117.51
Investment Opinion: Should I buy CVSA Today?
The synthesized recommendation is a Hold, reflecting a balance between deep value on forward earnings and significant near-term operational challenges. The analyst consensus rating is "buy" with a mean of 1.75, and the average target price of $159.50 implies 32.1% upside, but the stock's recent price action and decelerating revenue growth warrant caution. The core thesis is that CVSA is a cash-generative, profitable education provider trading at a discount on forward earnings, but the market is skeptical of the earnings acceleration required to justify the bullish targets.
Supporting evidence for the Hold includes the forward PE of 12.07x, which is low in absolute terms and suggests the market expects substantial earnings growth; the trailing PE of 17.36x is moderate. Revenue growth has decelerated to 4.5% YoY, but the company maintains a net margin of 12.87% and operating margin of 19.94%. Free cash flow yield is strong at approximately 7.7%, funding aggressive buybacks (over $67 million in the latest quarter). The implied upside to the average analyst target is 32.1%, but the wide target range ($140-$175) and thin coverage (4 analysts) reduce conviction.
The biggest risks that could invalidate the thesis are a further deceleration in revenue growth below 4%, margin compression, and a failure to achieve the forward EPS estimate of $11.11. The rating would upgrade to Buy if revenue growth stabilizes above 5% and margins expand, or if the stock drops below $100 (near the 52-week low) offering a better risk/reward. It would downgrade to Sell if revenue growth turns negative or if free cash flow declines significantly. Relative to its history, the forward PE of 12.07x is near the low end, suggesting the stock is undervalued on forward earnings, but the PB ratio of 3.02x is in the upper half of its historical range, indicating a mixed valuation picture.
Sign up to view all
CVSA 12-Month Price Forecast
The forward-looking view is neutral with medium confidence, balancing the stock's deep value on forward earnings against its decelerating revenue growth and weak price momentum. The company's strong free cash flow and buyback program provide support, but the market is clearly skeptical of the earnings acceleration implied by the forward EPS estimate of $11.11. The divergence between bullish analyst targets and bearish price action suggests that a catalyst is needed to resolve the direction. I would upgrade to bullish if revenue growth stabilizes above 5% and margins expand, or downgrade to bearish if revenue growth turns negative or if the stock breaks below the 52-week low of $86.97.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Covista Inc.'s 12-month outlook, with a consensus price target around $159.50 and implied upside of +35.7% versus the current price.
Average Target
$159.50
0 analysts
Implied Upside
+35.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$140 - $175
Analyst target range
Coverage of CVSA is thin, with only 4 analysts contributing to the consensus, but sentiment is decidedly bullish: the recommendation is "buy" with a recommendation mean of 1.75 (where 1.0 is a strong buy and 3.0 is a hold), and the average target price of $159.50 implies roughly 32.1% upside from the current price of $120.75. The consensus EPS estimate of $11.11 for the forward period, against a trailing quarterly EPS run-rate that annualizes to roughly $6.68, implies analysts expect substantial earnings acceleration — a view that may be optimistic given the recent revenue deceleration to 4.5% YoY growth. The bullish consensus stands in stark contrast to the stock's weak recent price action, creating a notable divergence between analyst expectations and market behavior.
The target range spans from a low of $140.00 to a high of $175.00, a spread of $35 (25% of the low target), which signals moderate rather than high conviction among the small analyst cohort. The high target of $175 would require roughly 45% upside and likely assumes multiple expansion back toward the stock's historical premium plus successful execution on margin expansion and buybacks, while the low target of $140 still implies 15.9% upside and may simply reflect a more conservative earnings multiple. Institutional ratings show a pattern of steady reiterations — Barrington Research has maintained "Outperform" across eight consecutive actions from September 2025 through June 2026, and Truist Securities reiterated "Buy" in May 2026 — with no downgrades or upgrades, indicating stable but unenthusiastic coverage. The lack of recent rating changes, combined with the wide target spread and thin coverage, suggests limited institutional engagement and the potential for inefficient price discovery, which could amplify volatility around future earnings reports.
Bulls vs Bears: CVSA Investment Factors
The bear case currently has stronger evidence due to the sharp deceleration in revenue growth to 4.5% YoY, negative price momentum, and weak relative strength versus the market. However, the bull case rests on compelling valuation metrics—forward PE of 12.07x and a 7.7% FCF yield—and significant analyst upside of 32.1% to the average target. The most important tension is whether the company can sustain earnings growth through margin expansion and buybacks as revenue growth moderates; if it can, the stock is deeply undervalued, but if growth stalls further, the low forward PE could prove to be a value trap. The divergence between bullish analyst targets and bearish price action suggests the market is skeptical of the earnings acceleration implied by estimates.
Bullish
- Deep Value on Forward Earnings: The forward PE of 12.07x is near the low end of the stock's historical earnings multiple range and sits well below the trailing PE of 17.36x. This implies the market is pricing in roughly 44% earnings growth over the next year, yet the stock trades at a discount to broad market multiples on forward earnings, creating a potential value opportunity if estimates are met.
- Strong Free Cash Flow Yield: Trailing twelve-month free cash flow of $336.28 million against a market cap of $4.37 billion yields approximately 7.7%, a robust cash generation profile. This cash flow funds an aggressive buyback program, with over $67 million repurchased in the latest quarter alone, reducing share count and supporting EPS growth.
- Analyst Consensus Upside: The consensus analyst target price of $159.50 implies 32.1% upside from the current price of $120.75, with a recommendation mean of 1.75 (buy). Even the low target of $140.00 suggests 15.9% upside, indicating that the small analyst cohort sees significant value despite recent price weakness.
- Improving Profitability and Operating Leverage: The latest quarter posted a net margin of 12.87% and operating margin of 19.94%, with gross margin at 57.34%. Despite revenue growth moderating to 4.5% YoY, the company maintains healthy profitability, and the operating leverage inherent in the education model could drive margin expansion if enrollment trends stabilize.
Bearish
- Decelerating Revenue Growth: Revenue growth has slowed to just 4.5% YoY in the latest quarter, down from higher rates in prior periods, and sequential revenue declined from $503.39 million in Q2 to $487.03 million in Q3. This mid-single-digit growth profile pressures the valuation multiple and suggests the investment case now relies more on margin expansion and buybacks than top-line acceleration.
- Weak Relative Strength and Price Momentum: CVSA has badly lagged the market, with relative strength versus SPY at -13.05% over 1 month, -11.13% over 3 months, and -16.29% over 6 months. The 1-month price change of -12.36% and 3-month change of -5.32% diverge from the positive 6-month trend, signaling deceleration that could precede further downside.
- Margin Volatility and Earnings Decline: Net income fell sequentially from $76.38 million in Q2 to $41.64 million in Q3, partly due to a higher effective tax rate (25.6% vs. 25.3%) and lower operating income ($92.21 million vs. $111.11 million). Gross margin also declined from 59.19% to 56.73% sequentially, highlighting earnings volatility.
- Thin Analyst Coverage and Wide Target Spread: Only 4 analysts cover CVSA, and the target range spans from $140 to $175, a $35 spread (25% of the low target). This signals moderate conviction and limited institutional engagement, which could amplify volatility around earnings reports and lead to inefficient price discovery.
CVSA Technical Analysis
CVSA is in a choppy, range-bound consolidation phase rather than a clean trend, with the current price of $120.75 sitting roughly 22.7% below its 52-week high of $156.26 and about 38.8% above its 52-week low of $86.97 — placing it at approximately 51% of its 52-week range. The 6-month price change of +5.36% confirms a modestly positive intermediate trend, but the stock has surrendered much of its earlier gains, and the -3.41% one-year price change signals that longer-term holders are essentially flat. This mid-range positioning means the stock is neither a momentum breakout candidate nor a deeply discounted falling knife, but rather a name in need of a catalyst to resolve direction.
Recent momentum has deteriorated sharply: the 1-month change of -12.36% and 3-month change of -5.32% are both deeply negative and diverge from the positive 6-month trend, a classic deceleration signal that often precedes either a trend reversal or a mean-reversion bounce. Relative strength versus SPY is uniformly weak across timeframes — -13.05% over 1 month, -11.13% over 3 months, and -16.29% over 6 months — meaning CVSA has lagged the market badly even as SPY gained 0.69% (1M), 5.81% (3M), and 21.65% (6M). The most recent session saw a -2.75% drop on volume of 525,851 shares, and with a short ratio of 5.84 days, there is meaningful short interest that could amplify either further downside or a squeeze on any positive surprise.
Key technical levels are defined by the 52-week low at $86.97 as major support and the 52-week high at $156.26 as resistance, with the stock's max drawdown of -17.31% showing it can shed value quickly when sentiment turns. A breakout above the $140-$156 resistance zone would signal renewed institutional conviction and likely require a fundamental catalyst, while a breakdown below the $115-$117 area (recent consolidation lows) could open the door toward the $100 handle and ultimately the 52-week low. With a beta of just 0.626, CVSA is roughly 37% less volatile than the broader market, which argues for smaller position-sizing adjustments and suggests the stock's recent weakness is company-specific rather than macro-driven.
Beta
0.63
0.63x market volatility
Max Drawdown
-17.3%
Largest decline past year
52-Week Range
$87-$156
Price range past year
Annual Return
—
Cumulative gain past year
| Period | CVSA Return | S&P 500 |
|---|---|---|
| 1m | -12.6% | -0.5% |
| 3m | -5.7% | +2.5% |
| 6m | +0.7% | +16.8% |
| 1y | — | +15.7% |
| ytd | — | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CVSA Fundamental Analysis
Covista's revenue trajectory is one of steady but decelerating growth: the most recent quarter (ending 2026-03-31) posted revenue of $487.03 million with year-over-year growth of just 4.5%, a marked slowdown from the prior-year comparable quarter's $466.06 million (which itself grew from $417.40 million a year earlier). The multi-quarter progression — $457.11M, $462.29M, $503.39M, and $487.03M — shows sequential revenue that peaked in the December quarter and has since moderated, with the Q3 figure actually declining sequentially from Q2's $503.39M. This mid-single-digit growth profile implies the investment case now rests more on margin expansion and capital returns than on top-line acceleration, and any further deceleration would pressure the valuation multiple.
Profitability remains solid and is improving: net income of $41.64 million in the latest quarter translated to a net margin of 12.87%, while the gross margin of 57.34% and operating margin of 19.94% reflect a business with meaningful operating leverage. However, comparing across quarters reveals margin volatility — gross margin was 59.19% in the December quarter and 56.73% in the March quarter, while net income fell from $76.38 million to $41.64 million sequentially, partly due to a higher effective tax rate (25.6% vs. 25.3%) and lower operating income ($92.21 million vs. $111.11 million). The trailing EPS of $0.058 appears distorted by share-count or one-time items, but the quarterly diluted EPS of $1.67 and forward EPS estimate of $11.11 confirm the company is solidly profitable with a net margin of 12.87% that is respectable for the education services industry.
Balance sheet and cash flow metrics are healthy but not fortress-like: the debt-to-equity ratio of 0.626 and current ratio of 1.09 indicate moderate leverage with adequate short-term liquidity, while the ROE of 17.40% and ROA of 8.45% demonstrate efficient capital deployment. Free cash flow on a trailing-twelve-month basis is $336.28 million, which against a market cap of $4.37 billion implies an FCF yield of roughly 7.7% — a strong cash generation profile that funds the company's aggressive buyback program (over $67 million repurchased in the latest quarter alone). The interest coverage ratio of 6.77x and cash flow to debt ratio of 0.25 provide reasonable comfort, though the current ratio below 1.1 and quick ratio of 0.70 suggest limited liquidity buffer if operating conditions deteriorate.
Quarterly Revenue
$487030000.0B
2026-03
Revenue YoY Growth
+4.5%
YoY Comparison
Gross Margin
56.7%
Latest Quarter
Free Cash Flow
$336279000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CVSA Overvalued?
Because Covista is profitable with positive net income of $41.64 million and trailing EPS of $0.058 (distorted by share count), the PE ratio is the appropriate primary metric; the trailing PE of 17.36x versus a forward PE of 12.07x implies the market expects earnings to grow roughly 44% over the next year, a substantial gap that reflects either optimistic analyst estimates or the distortion in trailing EPS. The forward PE of 12.07x is notably low in absolute terms, suggesting the market is pricing in significant earnings growth that has yet to materialize in reported results, and the PEG ratio of 1.20 indicates the stock is reasonably valued relative to its expected growth rate.
Against the broader Personal Products & Services industry, CVSA's valuation appears mixed: the PS ratio of 2.24x and EV/Sales of 2.42x are moderate, while the EV/EBITDA of 10.42x and PB ratio of 3.02x suggest the market is paying a modest premium for the company's asset-light education model. The net margin of 12.87% and operating margin of 19.94% are healthy for the sector, which helps justify the PB premium, but the PCF ratio of 9.29x and price-to-free-cash-flow ratio of 23.81x indicate cash flow valuation is less stretched. Without explicit industry average multiples in the provided data, the most defensible read is that CVSA trades at a slight premium to broad market multiples on book value but at a discount on forward earnings, creating a mixed valuation picture.
Historically, CVSA's valuation has compressed dramatically: the PE ratio has fallen from 22.85x in the September 2025 quarter to 17.05x in the March 2026 quarter, while the PS ratio collapsed from 12.52x to 8.11x over the same period — though the current reported PS of 2.24x suggests a different share-count basis. The PB ratio has ranged from a low of 0.99x in mid-2023 to a high of 3.97x in late 2025, and the current 3.02x sits in the upper half of that historical band, implying the market still assigns a premium to the franchise despite the recent price weakness. The forward PE of 12.07x, if accurate, would be near the low end of the stock's historical earnings multiple range, which could signal either a value opportunity or a market that doubts the sustainability of projected earnings growth.
PE
17.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 9x~23x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks for Covista are centered on its decelerating revenue growth and margin volatility. Revenue grew just 4.5% YoY in the latest quarter, down from prior periods, and sequential revenue declined from $503.39 million to $487.03 million. Net income fell sequentially from $76.38 million to $41.64 million, partly due to a higher effective tax rate and lower operating income, while gross margin compressed from 59.19% to 56.73%. The current ratio of 1.09 and quick ratio of 0.70 indicate limited liquidity buffer, and the debt-to-equity ratio of 0.626 reflects moderate leverage that could become burdensome if cash flows weaken.
Market and competitive risks include the stock's significant underperformance relative to the broader market, with relative strength versus SPY at -13.05% over 1 month and -16.29% over 6 months. The forward PE of 12.07x is low, but if earnings growth fails to materialize, the multiple could compress further. The education sector faces regulatory risks, and competition from traditional non-profit universities and other for-profit providers could pressure enrollment and pricing. With a beta of 0.626, the stock is less volatile than the market, but its recent weakness appears company-specific, suggesting internal challenges rather than macro headwinds.
The worst-case scenario would involve a continued deceleration in revenue growth, margin compression, and a failure to meet the optimistic forward EPS estimate of $11.11. This could trigger analyst downgrades and a decline toward the 52-week low of $86.97, representing a potential loss of approximately 28% from the current price of $120.75. The max drawdown of -17.31% shows the stock can shed value quickly, and with a short ratio of 5.84 days, short sellers could amplify downside momentum. In a severe scenario, the stock could test the 52-week low, implying a -28% return.
FAQ
The key risks for CVSA include: 1) Financial risk: Revenue growth has decelerated to 4.5% YoY, and net income fell sequentially from $76.38 million to $41.64 million, with a current ratio of 1.09 indicating limited liquidity. 2) Competitive risk: The education sector is highly competitive, and CVSA faces pressure from traditional non-profit universities and other for-profit providers. 3) Macro risk: With a beta of 0.626, the stock is less volatile than the market, but its recent weakness is company-specific, suggesting internal challenges. 4) Company-specific risk: Thin analyst coverage (4 analysts) and a wide target range ($140-$175) mean a single downgrade could significantly impact the stock. The most severe risk is a continued revenue deceleration leading to a test of the 52-week low of $86.97.
The 12-month forecast for CVSA includes three scenarios: Bull case (25% probability) targets $159.50-$175.00, assuming successful margin expansion and earnings growth. Base case (50% probability) targets $130-$145, assuming low-to-mid single-digit revenue growth and stable margins. Bear case (25% probability) targets $86.97-$100, assuming revenue declines and margin compression. The base case is most likely, with the key assumption that revenue growth remains between 3% and 5% YoY and net margin stays around 12-13%. The stock is currently trading at $120.75, so the base case implies roughly 8-20% upside, while the bear case implies 17-28% downside.
CVSA appears undervalued on forward earnings, with a forward PE of 12.07x compared to a trailing PE of 17.36x, suggesting the market expects significant earnings growth. The PEG ratio of 1.20 indicates a reasonable valuation relative to expected growth. However, the PB ratio of 3.02x is in the upper half of its historical range (0.99x to 3.97x), indicating a premium on book value. The PS ratio of 2.24x and EV/EBITDA of 10.42x are moderate for the education sector. Overall, the valuation is mixed: cheap on forward earnings but not on book value. The market is pricing in roughly 44% earnings growth, so if that fails to materialize, the stock could be overvalued.
CVSA presents a mixed risk/reward profile. On the positive side, the stock trades at a forward PE of 12.07x, near historical lows, and offers a 7.7% free cash flow yield, with analyst targets implying 32.1% upside to $159.50. However, revenue growth has decelerated to 4.5% YoY, and the stock has weak relative strength, lagging the market by over 16% in six months. The biggest downside risk is a continued deceleration that could push the stock toward its 52-week low of $86.97, a 28% decline. For value investors with a medium-term horizon and tolerance for volatility, it could be a good buy if earnings estimates are met, but it is not suitable for those seeking momentum or near-term gains.
CVSA is more suitable for long-term investment than short-term trading. The company is in a moderate growth stage with a beta of 0.626, indicating lower volatility than the market, and pays no dividend (payout ratio 0). Earnings visibility is moderate, with analyst estimates for forward EPS of $11.11, but the stock has shown significant volatility with a max drawdown of -17.31% and a 52-week range of $86.97 to $156.26. Short-term trading would require timing the volatile price swings, which is risky given the thin analyst coverage and lack of recent news. A suggested minimum holding period is 12-18 months to allow for potential earnings growth and multiple expansion to materialize.